Safety of Immunosuppression Minimization in Children and Adolescents After Kidney Transplantation
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT00768729 |
|
Recruitment Status :
Completed
First Posted : October 8, 2008
Last Update Posted : February 15, 2013
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Kidney Failure, Chronic Kidney Transplantation Immunosuppression | Drug: Sirolimus Drug: MMF or Azathioprine | Phase 1 |
Improvements in surgical techniques, donor selection, immunosuppression practices, and the enhanced experience of specialized pediatric transplant teams have all led to marked improvements in patient and kidney graft survival in infants and young children Long-term graft survival rates decrease in adolescents 11 to 17 years of age. Several studies have suggested this decrease may be the result of noncompliance with immunosuppressive medications in this age group. Therefore, protocols that minimize the use of immunosuppressive medications, while retaining kidney function are necessary for improving graft and patient survival in children. The purpose of this study is to determine the safety of sirolimus monotherapy for long-term immunosuppression in children and adolescents after kidney transplantation.
This study will enroll 10 participants who previously completed the CCTPT-PC01 study. The accrual period is scheduled for 12 months. The study follow-up period will last 96 weeks. Patients from the CCTPT-PC01 study have been maintained on sirolimus and mycophenolate mofetil (MMF) since 2-3 months post transplant. Enrolled participants receiving (MMF) or Azathioprine at study entry will have their doses withdrawn gradually over a period of 6 months. Dosage will be reduced by 25% initially and by 25% every 2 months resulting in complete withdrawal by 6 months.
This study will consist of 11 study visits after screening and study entry. Study visits will occur at weeks 1, 8, 16, 24, 32, 40, 48, 60, 72, 84, and 96. A physical exam, vital signs, sirolimus levels, as well as blood and urine collection will occur at all visits. A renal biopsy will be performed at week 96.
| Study Type : | Interventional (Clinical Trial) |
| Actual Enrollment : | 7 participants |
| Allocation: | Non-Randomized |
| Intervention Model: | Single Group Assignment |
| Masking: | None (Open Label) |
| Primary Purpose: | Prevention |
| Official Title: | Immunosuppression Minimization to Single Drug Therapy With Sirolimus (Rapamune) in Pediatric Transplantation |
| Study Start Date : | May 2009 |
| Actual Primary Completion Date : | December 2012 |
| Actual Study Completion Date : | December 2012 |
| Arm | Intervention/treatment |
|---|---|
|
Experimental: 1
Participants who have been maintained on MMF at study entry will start the study on 600 mg/m2 MMF orally daily. Participants who have been maintained on Azathioprine due to MMF intolerance will receive 1 mg/kg Azathioprine orally daily. Participants will continue receiving sirolimus throughout the study. However, MMF or Azathioprine will be withdrawn gradually over a period of at least 6 months. Dosage will be reduced by 25% initially and by 25% every subsequent 2 months resulting in complete withdrawal by 6 months. |
Drug: Sirolimus
Oral tablets or liquid taken every 12 hours. Dosage adjusted to attain target trough levels of 8-12 ng/mL. Participants who have maintained such levels at study entry on once daily dosage will be permitted to continue on once daily dosing.
Other Name: Rapamycin, Rapamune Drug: MMF or Azathioprine 600 mg/m2 MMF taken orally daily or Azathioprine orally daily. Dosage of Azathioprine is dependent on weight. MMF or Azathioprine will be reduced by 25% initially and by 25% every 2 months resulting in complete withdrawal by 6 months. |
- Per-person incidence of acute rejection episodes and death or graft loss [ Time Frame: Throughout study ]
- Incidence of chronic allograft dysfunction [ Time Frame: Throughout study ]
- Incidence of sub-clinical rejection [ Time Frame: Throughout study ]
- Incidence of hospitalizations [ Time Frame: Throughout study ]
- Incidence of surgical complications [ Time Frame: Throughout study ]
- Resumption of MMF or other therapy [ Time Frame: Throughout study ]
- Incidence, severity, and treatment of anemia, hypertension, hyperlipidemia, proteinuria, thrombocytopenia, and leukopenia [ Time Frame: Throughout study ]
- Incidence, severity, and treatment of opportunistic infections [ Time Frame: Throughout study ]
- Incidence of biopsy proven PTLD [ Time Frame: Throughout study ]
- Renal function assessed by measured GFR [ Time Frame: At baseline, week 48 and week 96 ]
- Development of donor-specific or non-specific anti-HLA antibodies [ Time Frame: Throughout study ]
- Evolution of immune response in cellular, humoral, and molecular assays from baseline through week 96 [ Time Frame: Throughout study ]
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 1 Year to 20 Years (Child, Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Participant and/or parent guardian able to understand and willing to provide informed consent
- Previously enrolled and completed the CCTPT-PC01 study and within the 36 months post-completion timeframe prior to study entry
- Currently receiving sirolimus and MMF or azathioprine therapy
- No history of acute rejection episodes
- No evidence of acute or chronic rejection on the 24 month CCTPT-PC01 protocol biopsy or any subsequent biopsy obtained after that time prior to study entry
- PRA (Class I and II) less than 5% at study entry
- No evidence of donor specific antibody at study entry
- Stable renal function with GFR greater than 60 cc/min 1.73M^2 using the Schwartz calculated method
- A negative pregnancy test for female participants of childbearing potential at study entry
- Agreement by female and male participants to use FDA approved methods of contraception.
Exclusion Criteria:
- Total lymphocyte count less than 400 mm^3
- Acute or chronic infection at study entry
- Treatment with investigational drug within 1 month prior to study entry
- Mental illness or history of drug or alcohol abuse that, in the opinion of the investigator, would interfere with the study
- History of allergic reaction to Iodine GFR assay
- History of malignancy within the past 12 months
- Inability or unwillingness to give informed consent or comply with the study protocol
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00768729
| United States, California | |
| Children's Hospital of Central California | |
| Madera, California, United States | |
| UCSF Children's Hospital | |
| San Francisco, California, United States | |
| United States, Massachusetts | |
| Children's Hospital, Boston | |
| Boston, Massachusetts, United States | |
| United States, Pennsylvania | |
| Children's Hospital, Philadelphia | |
| Philadelphia, Pennsylvania, United States | |
| United States, Washington | |
| Children's Hospital and Regional Medical Center, Seattle | |
| Seattle, Washington, United States | |
| Study Chair: | William H. Harmon, MD | Boston Children's Hospital |
Publications:
| Responsible Party: | National Institute of Allergy and Infectious Diseases (NIAID) |
| ClinicalTrials.gov Identifier: | NCT00768729 |
| Other Study ID Numbers: |
DAIT CTOTC-01 |
| First Posted: | October 8, 2008 Key Record Dates |
| Last Update Posted: | February 15, 2013 |
| Last Verified: | February 2013 |
|
End stage renal disease Kidney transplantation Renal transplantation Kidney failure Children Adolescents |
Sirolimus Rapamycin CellCept Mycophenolate mofetil (MMF) Azathioprine |
|
Renal Insufficiency Kidney Failure, Chronic Kidney Diseases Urologic Diseases Renal Insufficiency, Chronic Sirolimus Azathioprine Anti-Bacterial Agents Anti-Infective Agents Antibiotics, Antineoplastic |
Antineoplastic Agents Antifungal Agents Immunosuppressive Agents Immunologic Factors Physiological Effects of Drugs Antimetabolites Molecular Mechanisms of Pharmacological Action Antimetabolites, Antineoplastic Antirheumatic Agents |